Oral immunotherapy: The answer to peanut allergy?

REFERENCES

1. ↵
   1. Gupta RS,
   2. Warren CM,
   3. Smith BM, et al

   . The public health impact of parent-reported childhood food allergies in the United States. Pediatrics 2018; 142(6):e20181235. doi:10.1542/peds.2018-1235

   OpenUrlAbstract/FREE Full Text
2. ↵
   1. Food Allergy Research & Education (FARE)

   . Facts and statistics: key information to help better understand food allergies and anaphylaxis. Accessed January 21, 2021. https://www.foodallergy.org/resources/facts-and-statistics.
3. ↵
   1. Fierstein JL,
   2. Brown D,
   3. Gupta R,
   4. Bilaver L

   . Understanding food-related allergic reactions through a US national patient registry. J Allergy Clin Immunol Pract 2020; S2213–S2198(20)30827–8. doi:10.1016/j.jaip.2020.08.011

   OpenUrlCrossRef
4. ↵
   1. Sicherer SH,
   2. Muñoz-Furlong A,
   3. Godbold JH,
   4. Sampson HA

   . US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy Clin Immunol 2010; 125(6):1322–1326. doi:10.1016/j.jaci.2010.03.029

   OpenUrlCrossRefPubMed
5. ↵
   1. Hourihane JO,
   2. Dean TP,
   3. Warner JO

   . Peanut allergy in relation to heredity, maternal diet, and other atopic diseases: results of a questionnaire survey, skin prick testing, and food challenges. BMJ 1996; 313(7056):518–521. doi:10.1136/bmj.313.7056.518

   OpenUrlAbstract/FREE Full Text
6. ↵
   1. Lack G

   . Update on risk factors for food allergy. J Allergy Clin Immunol 2012; 129(5):1187–1197. doi:10.1016/j.jaci.2012.02.036

   OpenUrlCrossRefPubMed
7. ↵
   1. Gupta RS,
   2. Walkner MM,
   3. Greenhawt M, et al

   . Food allergy sensitization and presentation in siblings of food allergic children. J Allergy Clin Immunol Pract 2016; 4:(5)956–962. doi:10.1016/j.jaip.2016.04.009

   OpenUrlCrossRef
8. ↵
   1. Du Toit G,
   2. Roberts G,
   3. Sayre PH, et al

   . Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med 2015; 372(9):803–813. doi:10.1056/NEJMoa1414850

   OpenUrlCrossRefPubMed
9. ↵
   1. Hourihane JO,
   2. Roberts SA,
   3. Warner JO

   . Resolution of peanut allergy: case-control study. BMJ 1998; 316(7140):1271–1275. doi:10.1136/bmj.316.7140.1271

   OpenUrlAbstract/FREE Full Text
10. ↵
    1. Wasserman RL,
    2. Jones DH,
    3. Windom HH

    . Oral immunotherapy for food allergy: the FAST perspective. Ann Allergy Asthma Immunol 2018; 121(3):272–275. doi:10.1016/j.anai.2018.06.011

    OpenUrlCrossRef
11. ↵
    1. Chu DK,
    2. Wood RA,
    3. French S, et al

    . Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet 2019; 393(10187):2222–2232. doi:10.1016/S0140-6736(19)30420-9

    OpenUrlCrossRefPubMed
12. ↵
    1. Yu W,
    2. Freeland DMH,
    3. Nadeau KC

    . Food allergy: immune mechanisms, diagnosis and immunotherapy. Nat Rev Immunol 2016; 16(12):751–765. doi:10.1038/nri.2016.111

    OpenUrlCrossRef
13. ↵
    1. Feuille E,
    2. Nowak-Węgrzyn A

    . Oral immunotherapy for food allergies. Ann Nutr Metab 2016; 68(suppl 1):19–31. doi:10.1159/000445391

    OpenUrlCrossRef
14. 1. Freeland DMH,
    2. Manohar M,
    3. Andorf S,
    4. Hobson BD,
    5. Zhang W,
    6. Nadeau KC

    . Oral immunotherapy for food allergy. Semin Immunol 2017; 30:36–44. doi:10.1016/j.smim.2017.08.008

    OpenUrlCrossRef
15. ↵
    1. Palforzia

    . Prescribing information. Aimmune Therapeutics; 2020. Accessed January 21, 2021. https://www.fda.gov/media/134838/download.
16. ↵
    1. PALISADE Group of Clinical Investigators,
    2. Vickery BP,
    3. Vereda A,
    4. Casale TB, et al

    . AR101 oral immunotherapy for peanut allergy. N Engl J Med 2018; 379(21):1991–2001. doi:10.1056/NEJMoa1812856

    OpenUrlCrossRefPubMed
17. ↵
    1. Aimmune Therapeutics

    . Press release: new two-year Palforzia™ data show on-going safety and efficacy and continued immunomodulation in patients with peanut allergy. June 8, 2020. Accessed January 21, 2021. https://ir.aimmune.com/news-releases/news-release-details/new-two-year-palforziatm-data-show-going-safety-and-efficacy-and.
18. ↵
    1. US Food and Drug Administration

    . Approved risk evaluation and mitigation strategies (REMS): Palforzia (peanut (Arachis hypogaea) allergen powder-dnfp). Accessed January 21, 2021. https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=398.
19. ↵
    1. Shaker M,
    2. Greenhawt M

    . Estimation of health and economic benefits of commercial peanut immunotherapy products: a cost-effectiveness analysis. JAMA Netw Open 2019; 2(5):e193242. doi:10.1001/jamanetworkopen.2019.3242

    OpenUrlCrossRef
20. ↵
    1. Epstein-Rigbi N,
    2. Goldberg MR,
    3. Levy MB,
    4. Nachshon L,
    5. Elizur A

    . Quality of life of food-allergic patients before, during, and after oral immunotherapy. J Allergy Clin Immunol Pract 2019; 7(2):429–436.e2. doi:10.1016/j.jaip.2018.06.016

    OpenUrlCrossRef